172010jun
Prêmio Jovem Pesquisador – NCDEU
Dr. Moacyr recebe prêmio

Dr. Moacyr recebe prêmio

 2010 – NCDEU New Investigator Award


Dr. Moacyr Rosa, fundador do IPAN, teve a honra de ser escolhido, entre mais de 1200 candidatos, para receber o importante prêmio internacional de melhor Jovem Pesquisador.





A Premiação aconteceu na cidade de Boca Raton – Florida (USA), no dia 17 de Junho de 2010.

Saiba mais sobre EMTr AQUI!


Confira abaixo o prêmio:

O estudo premiado foi realizado na Universidade de Columbia e faz referência a uma inovadora técnica chamada de Estimulação Magnética Transcraniana repetitiva (EMTr) com Theta-Burst.

Trata-se de uma importante e promissora modalidade de tratamento para depressão. EMTr por Theta-Burst utiliza frequências acasaladas (por ex: 50Hz com 5Hz) de maneira similar ao ritmo cerebral. Desta forma, a EMTr por Theta-Burst desencadeia excitabilidade cortical com maior facilidade do que a EMTr.

“Theta-Burst Stimulation for the treatment of depression: efficacy, safety and mechanisms”.

Medication resistant depression is a debilitating condition that has few therapeutic options. These include a few device-based therapies that have received FDA approval for this indication, but that either have risks of significant side effects (e.g., electroconvulsive therapy), or are of limited efficacy in the most resistant patients (e.g., repetitive transcranial magnetic stimulation (rTMS), or both (vagus nerve stimulation).

Therefore, there remains a need to develop safe and effective treatments for the population of patients who are not adequately treated by available antidepressant medications and who suffer significant disability as a consequence. The FDA approval of TMS for depression a year ago was met with great enthusiasm and meta-analyses of numerous sham-controlled studies have shown TMS to produce statistically significant antidepressant effects with few, generally mild side effects, however, these studies have also shown inconsistent and relatively modest clinical improvements in depressed patients.

Therefore, there is a need to enhance the potency of TMS for it to have a meaningful role in clinical psychiatry. One of the most promising and innovative form of rTMS is called theta-burst stimulation (TBS). During conventional rTMS, pulses of stimulation are delivered in trains of a single arbitrary frequency (e.g., 1 Hz, 5 Hz, 10 Hz), while during TBS frequencies are coupled (usually 50 Hz coupled with 5 Hz) in ways that match endogenous neural oscillations. The theta burst pattern resembles a natural brain rhythm (such as that found in the hippocampus). This paradigm has shown to be a more potent means of enhancing cortical excitability than conventional rTMS. TBS has been used to treat some neurological disorders, such as amyotrophic lateral sclerosis, multiple sclerosis, stroke, dystonia and pain disorders, with promising results. For the treatment of psychiatric disorders, it has been used in one patient to treat negative symptoms in schizophrenia and in another to treat tinnitus associated with depression.

The current study will be a comparative trial of conventional rTMS with TBS to explore its relative efficacy to treat resistant major depression, and also to test its safety and side effects profile for this population. Finally, a noninvasive method to measure cortical excitability, called TMS evoked potentials, will be used as a physiological marker to evaluate the effects of both treatments on the stimulated area, i.e., the dorsolateral prefrontal cortex.

Sobre a NCDEU:

A NCDEU é um encontro científico focalizado no que há de mais atual em pesquisas clínicas. NCDEU is a scientific meeting that focuses on the latest developments in psychopharmacologic clinical research and related methodology. The meeting brings together over 1200 academic and industry investigators, research pharmacists, and clinicians, including competitively selected New Investigator awardees. In addition to the topics noted below, the NCDEU program includes presentations and information from the National Institute of Mental Health (NIMH), the American Society of Clinical Psychopharmacology (ASCP), and the Food and Drug Administration (FDA).